Spine

Lanman Spinal Neurosurgery Opens Up 2-Level prodisc®Cervical SK and Vivo Clinical Trial in Los Angeles

(LOS ANGELES) – FEB. 24, 2020 –Those suffering from advanced neck and arm pain may find themselves to be candidates for a new clinical trial that has opened up just this week at the Los Angeles-based practice, Lanman Spinal Neurosurgery, founded by one of the world’s most prominent spinal surgeons, Dr. Todd H. Lanman.

The practice, located in the heart of Beverly Hills, has begun open enrollment for a new patient study featuring two artificial cervical discs designed by spinal device manufacturer, Centinel Spine, including the prodiscC Vivo and prodiscC SK, as compared to the Mobi-C cervical disc, a currently marketed TDR (total disc replacement) device.

Patients experiencing pain in their neck and arms, between the ages of 18 and 69, with no prior surgeries in their cervical spine, who are chosen for the 2-to-1 randomized trial will undergo a surgery in which they will receive a prodiscC Vivo, prodiscC SK, or a Mobi-C. The 2-to-1 randomization ensures for every two patients getting a prodiscC Vivo or prodiscC SK, one patient will receive a Mobi-C.

The trial compares prodiscC SK and prodiscC Vivo with the approved, currently marketed TDR Mobi-C device as a control to compare safety and effectiveness to treat symptomatic cervical disc disease in subjects who have been unresponsive to non-operative, conservative treatment at two levels.

Disc replacement works by continuing to allow motion between the spinal levels, and with the prodisc devices, motion is provided by a ball and socket design, which allows for physiological range of motion while also ensuring stability to the spine. 

The prodisc cervical discs are low profile, allowing for “stacking” of discs at adjacent spinal levels, otherwise known as multilevel application. The prodiscC Vivo design uses “teeth” fixation to hold the device in place, while the prodiscC SK incorporates low-profile “keels” for fixation. During the clinical trial, Dr. Lanman will choose the appropriate prodisc design to fit the patient’s anatomic needs.  

Dr. Lanman and his Lanman Spinal Neurosurgery team have been at the forefront of spinal medicine and artificial disc replacement for many years, presiding over a majority of the spine world’s clinical trials and studies serving as a principal investigator, such as the Prestige LP and M6-C in recent years, leading to their FDA approvals. 

Lanman has been named one of the top doctors in his field by various high profile media outlets, and has been honored as a ‘Leader in Health Care’ by the Los Angeles Business Journal. A majority of his patients include A-level celebrities, sports players and business tycoons. He remains an associate professor at UCLA for two decades, has published countless peer-reviewed articles and book chapters relating to spine medicine, and serves as a frequent medical educator and expert contributor in the media. 

To be considered as a candidate for the trial, call (310) 385-7755 or email frontdesk@spine.md. Additional information about the clinical trial can be found at www.clinicaltrials.gov(NCT#04012996). 

For more information on Lanman Spinal Neurosurgery, visit www.spine.md.

Print Friendly, PDF & Email
Tags

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Back to top button
Close